Michael C. Diem, MD is the Senior Managing Partner of Pfizer Ventures and Vice President, Worldwide Business Development.  Mike is a member of Pfizer’s WWBD Leadership Team where he is responsible for leading Pfizer Ventures, managing the corporation’s equity portfolio, as well as overseeing equity-based transactions that support business development.

Mike has spent the last two decades as an executive and investor in the pharmaceutical and biotech industries.  Before joining Pfizer, Mike was the Chief Financial Officer and Chief Business Officer at Century Therapeutics. Prior to joining Century, he was Senior Vice President of Business and Corporate Development at Amicus Therapeutics, and prior to that, he held a similar role at Aevi Genomic Medicine. Earlier, Mike was the Global Head of Corporate Strategy and Corporate Development at AstraZeneca, where he was responsible for mergers and acquisitions, divestitures, and managed the company’s strategic investment activities and MedImmune Ventures. At GlaxoSmithKline (GSK), he led business development for the company’s rare disease business unit and was also a partner in GSK’s corporate venture firm, SR One, where he managed a portfolio of private and public companies. He has served on numerous corporate boards and is currently an independent director at Bloomsbury Genetic Therapies.

Dr. Diem obtained his MD from the Rutgers-Robert Wood Johnson Medical School, and an MBA from Case Western Reserve University. He completed his medical training at Duke University and is a Kauffman Fellow.

Email: [email protected]